Blueprint Medicines Debuts Comprehensive Preclinical Data Set on First Selective Drug for Patients with Systemic Mastocytosis at 2014 American Society of Hematology Annual Meeting

Blueprint Medicines, a leader in discovering and developing selective kinase drugs for patients with genetically defined diseases, today announced the presentation of its comprehensive set of preclinical data for BLU-285, the Company's lead program and the first drug to selectively block KIT D816V, the driver mutation in more than 95 percent of patients with systemic mastocytosis.

Full text here:

http://www.digitaljournal.com/pr/2382962